IN THIS ISSUE
Trust in big pharma has never been particularly high, but the results of Edelman’s Trust Barometer 2018 show that trust in pharma is falling significantly, especially in informed public markets such as the US, Germany and France. We find out what needs to change to prevent further decline.
Also, we explore the highs and lows of Humira, an arthritis drug with indications for colitis and psoriasis, to find out how it became the world’s top drug, and speak to the research team behind Bluebird Bio, which was recently singled out by MIT Technology Review as one of the top 50 smartest companies for its innovative technology and business model focused on gene therapy.
Plus, we investigate current and future treatment options for chronic migraines, find out about the new philanthropic arm of The International Society of Pharmaceutical Engineering, the ISPE Foundation, and get comment and analysis from GlobalData’s analysts.
Eloise McLennan, editor